Consistent with our findings, NVP-BEZ235 is effective in a mouse model of sporadic PI3KCA wild type CRC suggesting that the antitumor activity of ATP-competitive inhibitors of mTOR is not restricted to PI3KCA mutated colon cancer cells [30]. Here, MTOR is linked to malignant colon neoplasm.